- Home
- CISS vs SLRX Comparison
CISS vs SLRX Comparison
Compare CISS & SLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CISS
- SLRX
- Stock Information
- Founded
- CISS 2022
- SLRX N/A
- Country
- CISS Greece
- SLRX United States
- Employees
- CISS N/A
- SLRX N/A
- Industry
- CISS Marine Transportation
- SLRX Biotechnology: Pharmaceutical Preparations
- Sector
- CISS Consumer Discretionary
- SLRX Health Care
- Exchange
- CISS Nasdaq
- SLRX Nasdaq
- Market Cap
- CISS 2.5M
- SLRX 2.9M
- IPO Year
- CISS N/A
- SLRX N/A
- Fundamental
- Price
- CISS $2.65
- SLRX $5.69
- Analyst Decision
- CISS
- SLRX
- Analyst Count
- CISS 0
- SLRX 0
- Target Price
- CISS N/A
- SLRX N/A
- AVG Volume (30 Days)
- CISS 319.3K
- SLRX 285.6K
- Earning Date
- CISS 09-02-2025
- SLRX 11-13-2025
- Dividend Yield
- CISS N/A
- SLRX N/A
- EPS Growth
- CISS N/A
- SLRX N/A
- EPS
- CISS 5.74
- SLRX N/A
- Revenue
- CISS $38,084,901.00
- SLRX N/A
- Revenue This Year
- CISS N/A
- SLRX N/A
- Revenue Next Year
- CISS N/A
- SLRX N/A
- P/E Ratio
- CISS $0.39
- SLRX N/A
- Revenue Growth
- CISS N/A
- SLRX N/A
- 52 Week Low
- CISS $2.03
- SLRX $4.50
- 52 Week High
- CISS $18.75
- SLRX $108.00
- Technical
- Relative Strength Index (RSI)
- CISS 47.52
- SLRX 44.79
- Support Level
- CISS $2.18
- SLRX $4.79
- Resistance Level
- CISS $3.80
- SLRX $5.65
- Average True Range (ATR)
- CISS 0.18
- SLRX 0.45
- MACD
- CISS 0.00
- SLRX 0.25
- Stochastic Oscillator
- CISS 58.49
- SLRX 66.85
About CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of our fleet is approximately 64,000 dwt.
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.